title: Asthma pharmacogenomics.
abstract: It is expected that future treatments will be preceded by genetic tests to prescribe the most effect asthma medication while lowering the risk of adverse side effects. However, it will not be necessary to describe all the genetic determinants affecting drug response to apply pharmacogenomics to asthma therapy. Whether pharmacogenomics becomes common practice may not depend on the availability of tests, but on factors such as affordability, ease of application, and ease of interpreting the results.
authors.affiliation: Center for Human Genomics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. ghawkins@wfubmc.edu
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Hawkins
authors.forename: Scott T
authors.initials: ST
authors.lastname: Weiss
authors.forename: Eugene R
authors.initials: ER
authors.lastname: Bleecker
mesh_terms: D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D015195:Drug Design; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D010597:Pharmacogenetics / Q000639:trends*
chemical_list: D004364:Pharmaceutical Preparations